Medicare Advantage Step Therapy for Wet AMD: Ongoing Treatment, Appeals and Medigap

Some Medicare Advantage plans use step therapy for Part B drugs, but an “Avastin first” rule is not universal. Check your exact plan’s written policy, whether the request is for a new administration or ongoing treatment, and what decision has actually been made. If the prescribed visit is at risk, contact the retina team now rather than choosing your own waiting period.

U.S. Medicare information checked October 15, 2026. Regulations, plan policies and enrollment rights can change. This guide explains access questions; your retina specialist determines appropriate treatment.

Separate three different issues

• Step therapy: a rule about trying a plan-preferred drug before another drug is covered.
• Prior authorization: a review before the plan agrees to cover a requested treatment. It may involve step therapy, but the two terms are not interchangeable.
• A denial: an adverse coverage decision with a reason and appeal rights. “Not submitted,” “information requested” and “denied” are different statuses.

Avastin, Eylea and Vabysmo are examples of names you may hear. They do not form a universal sequence that every patient must follow. Do not change medication, stop injections or delay care based on a comparison of brand names in an insurance article.

If you already receive the drug, ask about the treatment-history protection

42 CFR 422.136 requires a Medicare Advantage plan using Part B drug step therapy to apply it only to new administrations, using a lookback of at least 365 days. This is more specific than simply asking whether the eye is “stable.”

Ask the clinic to provide the exact drug and administration dates, including records from a previous clinic when relevant. Ask the plan which written criterion it is applying and how it evaluated that history. The protection does not mean that every future claim must be paid regardless of medical necessity, other coverage requirements or the facts of the case.

If a step is clinically inappropriate, ask the prescriber and plan about the exception process and supporting evidence. A relevant clinical explanation is more useful than a demand for a particular phrase in the chart. Do not invent previous treatment failure, symptoms or response to obtain approval.

Confirm the request and its deadline

Ask the clinic’s authorization team what it submitted, and ask the plan when it received the request. Keep a reference number, drug name, requested service date and written status. A general benefits answer that a drug “may be covered” is not a decision on your request.

For an initial Medicare Advantage Part B drug organization determination, 42 CFR 422.568(b)(3) requires notification as quickly as health requires, no later than 72 hours after receipt. For an approved expedited Part B drug determination, 42 CFR 422.572(a)(2) sets a maximum of 24 hours after receipt, again as quickly as health requires. Those Part B drug periods cannot be extended under the provisions identified in those sections.

These are decision limits for the specified request, not promises of approval, injection availability or a medically safe delay. Other service, payment and appeal requests have different rules. If waiting could jeopardize health or vision, ask the retina specialist to support the appropriate expedited route. Do not use a “comfort cushion” calculator to decide when to seek clinical advice.

If the plan denies coverage, preserve the appeal route

Request the written denial and read its reason, instructions and deadline with the clinic. Missing records may be correctable, but a denial may also involve a disputed coverage criterion. Do not assume it is merely incomplete paperwork or that resubmitting a fax replaces an appeal.

CMS’s Medicare Advantage reconsideration guidance states that a plan appeal is generally requested within 65 calendar days from the date of the organization-determination notice. It lists a maximum of seven calendar days for a standard Part B drug reconsideration and 72 hours for an expedited Part B drug reconsideration, with decisions as quickly as health requires. These are appeal timeframes, separate from the initial 72-hour and 24-hour limits above.

Follow the notice rather than waiting until the last day. Ask about a fast appeal when standard timing could seriously jeopardize health or function. Keep submission confirmation. If the plan’s reconsideration remains unfavorable in whole or part, CMS describes automatic forwarding to the Part C Independent Review Entity. A complaint about service can address a separate concern, but should not substitute for the coverage appeal.

What Original Medicare and Medigap change

Medicare’s macular-degeneration coverage page says Part B may cover certain tests and treatments, including certain injectable drugs. Under Original Medicare, after the Part B deductible, the usual patient share is 20% of the Medicare-approved amount for covered care. A hospital outpatient setting can involve an additional copayment. Obtain a setting-specific estimate rather than multiplying a drug’s retail price by 20%.

Medigap supplements Original Medicare and can help with covered Part A and Part B cost sharing according to the policy. It is not coverage to add to Medicare Advantage and is not a tool for overruling an Advantage drug decision. Original Medicare still has coverage and medical-necessity requirements; changing systems does not guarantee a particular drug or immediate appointment.

Medicare explains how Medigap works, including that newly purchased policies do not include Part D prescription coverage. When considering a change, account for outpatient prescription coverage as well as injection visits, premiums, provider participation and cost sharing.

Check Medigap eligibility before leaving a plan

The ability to leave Medicare Advantage and the right to buy Medigap are separate questions. The annual Medicare enrollment period does not itself guarantee Medigap acceptance. Medicare’s Medigap buying guide describes a six-month open enrollment period beginning the first month you are 65 or older and enrolled in Part B. Outside protected situations, there may be no federal guarantee that an insurer will sell you a policy, and health history can affect availability or cost. Trial rights, other guaranteed-issue rights and state protections may apply.

Before making a change, confirm your individual rights, application outcome, premiums and effective dates. Coordinate the end of the old coverage, start of the new coverage and any separate drug plan. Confirm that the retina clinic accepts the proposed coverage and can maintain the prescribed treatment. Do not cancel coverage on the assumption that Medigap will be available later.

The State Health Insurance Assistance Program offers local Medicare counseling. Bring your current plan documents and proposed change to a counselor or your State Insurance Department; a clinician’s billing team can confirm treatment logistics but cannot establish every enrollment right.

A short call script and record to keep

Use these suggested questions, adapted to your situation:

1. “What exact drug and service date are on the request, and when did the plan receive it?”
2. “Is the issue step therapy, prior authorization, missing records or a written denial? Please identify the applicable policy.”
3. “How was my previous treatment evaluated under the Part B step-therapy lookback rule?”
4. “Does the retina team consider expedited review or an exception appropriate? Who will submit it?”
5. “What is the next action, who is responsible, and when should I follow up? Please give me a reference number and a copy of any decision.”

Keep the actual appointment, current treatment history, submission dates, notices and appeal confirmations together. If transport is also a problem, the injection-visit transport guide can help you arrange support. Neither an authorization deadline nor an insurance change replaces the clinical plan.

New vision symptoms need medical advice separately from the insurance process. Contact the retina team urgently about new distortion, a central dark area or worsening vision. Sudden inability to see or sudden severe eye pain needs emergency assessment; do not wait for an authorization decision or drive yourself. See official urgent vision-loss guidance and your clinic’s own emergency instructions.